To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Pegylated liposomal doxorubicin|DRUG: Epirubicin|DRUG: Cyclophosphamid|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Docetaxel
Sponsor: Shanghai Pudong Hospital
Collaborators: CSPC Ouyi Pharmaceutical Co., Ltd.